This article is more than 5 years old. Information may no longer be current.

ONL Therapeutics awarded NEI grant to develop treatment for retinal disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The National Eye Institute awarded ONL Therapeutics a $1.37 million grant to develop ONL101, a first-in-class small molecule peptide designed to protect photoreceptors in retinal detachment, according to a press release.

ONL101 was previously given orphan drug designation for retinal detachment.

The Small Business Innovation Research (SBIR) phase 2 contract will be used to support the conclusion of preclinical development stages required for an investigational new drug application. The grant follows a phase 1 SBIR project that focused on the feasibility of blocking photoreceptor apoptosis in animal models of retinal detachment.

“Illustrating this mechanism of photoreceptor protection not only helps advance ONL101 as a treatment for retinal detachment but also provides rationale for the technology’s application to other important retinal diseases such as wet and dry age-related macular degeneration,” John Freshley, CEO of ONL Therapeutics, said in the release.

The company expects to submit an investigational new drug application in late 2015 to start a phase 1 clinical trial of ONL101 in retinal detachment.